Kocks, Janwillem W. H. http://orcid.org/0000-0002-2760-0693
Chrystyn, Henry
van der Palen, Job
Thomas, Mike
Yates, Louisa
Landis, Sarah H.
Driessen, Maurice T.
Gokhale, Mugdha
Sharma, Raj
Molimard, Mathieu
Funding for this research was provided by:
GlaxoSmithKline (NA, NA, NA, NA, NA, NA, NA, NA, NA)
Article History
Received: 13 February 2018
Accepted: 17 October 2018
First Online: 16 November 2018
Competing interests
: Janwillem W.H. Kocks declares grants and personal fees from AstraZeneca, Boehringer Ingelheim, GSK and Novartis, and grants from Chiesi, Mundipharma and Teva. Henry Chrystyn has received sponsorship to carry out studies, Board Membership, consultant agreements and honoraria for presentation, from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Innovata Biomed, Meda, Mundipharma, Napp Pharmaceuticals, NorPharma, Novartis, Orion, Sanofi, Teva, Trudell Medical International, UCB, and Zentiva. He has also received research sponsorship from grant-awarding bodies (EPSRC and MRC). He is the owner of Inhalation Consultancy Ltd. Job van der Palen has received grant and travel funding from GSK. Mike Thomas has received personal fees from GSK, Novartis, Aerocrine, Boehringer Ingelheim, Teva, Pfizer, Roche, and Sandoz. He has also received non-financial support from GSK, Novartis, AstraZeneca, and Boehringer Ingelheim. Louisa Yates, Sarah Landis, Maurice Driessen, Raj Sharma, and Mugdha Gokhale are employed by, and hold stock in, GSK. Mathieu Molimard declares Board Membership and Consultancy with Almirall, AstraZeneca, BMS, GSK, Lundbeck, Mundipharma, Novartis Pharma, Otsuka, Pfizer, Stallergen, and Zentiva. He received payment for travel/accommodation/meeting expenses from Novartis Pharma.